Legend Biotech Corp
NASDAQ:LEGN
Legend Biotech Corp
Income from Continuing Operations
Legend Biotech Corp
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Legend Biotech Corp
NASDAQ:LEGN
|
Income from Continuing Operations
-$518.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-184%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Legend Biotech Corp's Income from Continuing Operations?
Income from Continuing Operations
-518.3m
USD
Based on the financial report for Dec 31, 2023, Legend Biotech Corp's Income from Continuing Operations amounts to -518.3m USD.
What is Legend Biotech Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-184%
Over the last year, the Income from Continuing Operations growth was -16%. The average annual Income from Continuing Operations growth rates for Legend Biotech Corp have been -25% over the past three years , -184% over the past five years .